董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Janet S. Vergis | 女 | Independent Director | 60 | 31.50万美元 | 0.99 | 2025-11-05 |
| Daniel T. Scavilla | 男 | President,Director,Chief Executive Officer and Interim Principal Financial Officer | 60 | 未披露 | 未持股 | 2025-11-05 |
| Jonathan J. Mazelsky | 男 | Independent Director | 64 | 未披露 | 未持股 | 2025-11-05 |
| Brian Gladden | 男 | Independent Director | -- | 未披露 | 未持股 | 2025-11-05 |
| Michael J. Barber | -- | Director | -- | 未披露 | 未持股 | 2025-11-05 |
| Clyde R. Hosein | 男 | Independent Director | 65 | 30.00万美元 | 0.63 | 2025-11-05 |
| Leslie F. Varon | 女 | Independent Director | 68 | 32.50万美元 | 2.38 | 2025-11-05 |
| Willie A. Deese | 男 | Independent Director | 69 | 32.00万美元 | 6.41 | 2025-11-05 |
| Betsy D. Holden | 女 | Independent Director | 69 | 31.50万美元 | 2.77 | 2025-11-05 |
| Gregory T. Lucier | 男 | Non-Executive Chairman of the Board | 60 | 30.00万美元 | 3.63 | 2025-11-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel T. Scavilla | 男 | President,Director,Chief Executive Officer and Interim Principal Financial Officer | 60 | 未披露 | 未持股 | 2025-11-05 |
| Robert A. Johnson | 男 | Chief Supply Chain Officer | 56 | 未披露 | 未持股 | 2025-11-05 |
| Andrea L. Frohning | -- | Senior Vice President and Chief Human Resources Officer | -- | 未披露 | 未持股 | 2025-11-05 |
| Kevin J. Czerney | -- | Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2025-11-05 |
董事简历
中英对照 | 中文 | 英文- Janet S. Vergis
-
Janet S. Vergis， 2013年1月至2019年12月，她担任私募股权公司的退休执行顾问，在那里她确定和评估医疗保健投资机会。从2011年1月到2012年8月，她担任OraPharma， Inc.（一家致力于口腔健康的专业制药公司）的首席执行官，在那里她领导了该公司的成功转型和随后的出售。从2004年到2009年，她担任Janssen Pharmaceuticals， McNeil Pediatrics and Ortho-McNeil Neurologics （Johnson & Johnson）的总裁。从1988年到2004年，她在Johnson & Johnson及其子公司担任行政领导、研发、新产品开发、销售和营销方面的各种职位。Vergis目前是Teva Pharmaceutical Industries（仿制药和生物制药的全球领导者）、Dentsply Sirona（全球最大的专业牙科解决方案制造商）和SGS（领先的测试、检验和认证公司）的董事会成员。她也是Amneal Pharmaceuticals， Inc.的董事会成员（2015年至2019年）。
Janet S. Vergis,is a retired Executive Advisor for private equity firms where she served in such capacity from January 2013 to December 2019, where she identified and evaluated healthcare investment opportunities. From January 2011 to August 2012, she was the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company dedicated to oral health, where she led that company's successful turnaround and its subsequent sale. From 2004 to 2009, Ms. Vergis served as President of Janssen Pharmaceuticals, McNeil Pediatrics and Ortho-McNeil Neurologics (Johnson & Johnson). From 1988 to 2004, she served in various positions of increasing responsibility in executive leadership, research and development, new product development, sales, and marketing with Johnson & Johnson and its subsidiaries.Ms. Vergis is currently a member of the board of directors of Teva Pharmaceutical Industries, a global leader in generics and biopharmaceuticals, Dentsply Sirona, the world's largest manufacturer of professional dental solutions and SGS, a leading testing, inspection and certification company. She was also a member of the board of directors of Amneal Pharmaceuticals, Inc. from 2015 to 2019. - Janet S. Vergis， 2013年1月至2019年12月，她担任私募股权公司的退休执行顾问，在那里她确定和评估医疗保健投资机会。从2011年1月到2012年8月，她担任OraPharma， Inc.（一家致力于口腔健康的专业制药公司）的首席执行官，在那里她领导了该公司的成功转型和随后的出售。从2004年到2009年，她担任Janssen Pharmaceuticals， McNeil Pediatrics and Ortho-McNeil Neurologics （Johnson & Johnson）的总裁。从1988年到2004年，她在Johnson & Johnson及其子公司担任行政领导、研发、新产品开发、销售和营销方面的各种职位。Vergis目前是Teva Pharmaceutical Industries（仿制药和生物制药的全球领导者）、Dentsply Sirona（全球最大的专业牙科解决方案制造商）和SGS（领先的测试、检验和认证公司）的董事会成员。她也是Amneal Pharmaceuticals， Inc.的董事会成员（2015年至2019年）。
- Janet S. Vergis,is a retired Executive Advisor for private equity firms where she served in such capacity from January 2013 to December 2019, where she identified and evaluated healthcare investment opportunities. From January 2011 to August 2012, she was the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company dedicated to oral health, where she led that company's successful turnaround and its subsequent sale. From 2004 to 2009, Ms. Vergis served as President of Janssen Pharmaceuticals, McNeil Pediatrics and Ortho-McNeil Neurologics (Johnson & Johnson). From 1988 to 2004, she served in various positions of increasing responsibility in executive leadership, research and development, new product development, sales, and marketing with Johnson & Johnson and its subsidiaries.Ms. Vergis is currently a member of the board of directors of Teva Pharmaceutical Industries, a global leader in generics and biopharmaceuticals, Dentsply Sirona, the world's largest manufacturer of professional dental solutions and SGS, a leading testing, inspection and certification company. She was also a member of the board of directors of Amneal Pharmaceuticals, Inc. from 2015 to 2019.
- Daniel T. Scavilla
-
Daniel T. Scavilla，自2025年2月起担任董事会成员以及董事会审计和财务委员会成员。Scavilla先生于2022年4月至2025年7月18日期间担任Globus Medical, Inc.（“Globus医疗”）的总裁兼首席执行官，领导其对NuVasive，Inc.的收购，并监督这两个组织的整合，以创建世界第二大脊柱技术公司，这家公司的市值约为80亿美元。在此之前，Scavilla先生是Globus医疗的执行副总裁、首席商务官兼Trauma总裁，在那里他扩展了制造和分销能力并推出了骨科和创伤业务部门，在此之前，他是Globus医疗的首席财务官。在加入Globus医疗之前，Scavilla先生在强生（“强生”）的不同业务中担任了28年的领导职务，包括担任J & J Vision Care全球财务与业务运营副总裁首席财务官，以及高级灭菌产品（强生医疗技术业务部门内的感染预防业务）全球财务副总裁首席财务官，帮助夺取灭菌领域第一的市场地位。强生的其他职位包括McNeil Consumer Healthcare（Kenvue）、Centocor和瑞士Cilag Schaffhausen Operations（杨森制药）的财务管理职位。Scavilla先生在Globus医疗董事会任职，并且是提名和公司治理委员会的成员。他此前曾于2021年11月至2023年7月担任Impulse Dynamics的董事会成员，该公司是一家私营医疗技术公司，专注于心力衰竭患者的微创治疗方案。Scavilla先生在拉萨尔大学获得金融和组织行为学学士学位，在天普大学获得国际管理硕士学位。
Daniel T. Scavilla,has served as a member of the Board and as a member of the Board's Audit and Finance Committee since February 2025. Mr. Scavilla served as President and Chief Executive Officer of Globus Medical, Inc. ("Globus Medical") from April 2022 through July 18, 2025, leading its acquisition of NuVasive, Inc. and overseeing the integration of the two organizations to create the second largest spine technology company in the world, a company with a market cap of approximately $8 billion. Prior to that, Mr. Scavilla was Executive Vice President, Chief Commercial Officer and President, Trauma, of Globus Medical where he scaled its manufacturing and distribution capabilities and launched its Orthopedics and Trauma business unit, and prior to that he was Chief Financial Officer of Globus Medical. Prior to joining Globus Medical, Mr. Scavilla spent 28 years in leadership roles across different businesses within Johnson & Johnson ("J&J"), including service as Chief Financial Officer, Worldwide Vice President Finance & Business Operations of J&J Vision Care, and as Chief Financial Officer, Worldwide Vice President Finance of Advanced Sterilization Products (J&J's infection prevention business within its MedTech business unit) helping to capture the number one market position in Sterilization. Additional roles at J&J included financial management positions at McNeil Consumer Healthcare (Kenvue), Centocor, and Cilag Schaffhausen Operations in Switzerland (Janssen Pharmaceutical). Mr. Scavilla serves on Globus Medical's Board of Directors and is a member of the Nominating and Corporate Governance Committee. He previously served on the board of directors of Impulse Dynamics, a privately held medical technology company focused on minimally invasive treatment options for heart failure patients, from November 2021 to July 2023. Mr. Scavilla received a B.S. in Finance and Organizational Behavior from LaSalle University and an M.B.A. in International Management from Temple University. - Daniel T. Scavilla，自2025年2月起担任董事会成员以及董事会审计和财务委员会成员。Scavilla先生于2022年4月至2025年7月18日期间担任Globus Medical, Inc.（“Globus医疗”）的总裁兼首席执行官，领导其对NuVasive，Inc.的收购，并监督这两个组织的整合，以创建世界第二大脊柱技术公司，这家公司的市值约为80亿美元。在此之前，Scavilla先生是Globus医疗的执行副总裁、首席商务官兼Trauma总裁，在那里他扩展了制造和分销能力并推出了骨科和创伤业务部门，在此之前，他是Globus医疗的首席财务官。在加入Globus医疗之前，Scavilla先生在强生（“强生”）的不同业务中担任了28年的领导职务，包括担任J & J Vision Care全球财务与业务运营副总裁首席财务官，以及高级灭菌产品（强生医疗技术业务部门内的感染预防业务）全球财务副总裁首席财务官，帮助夺取灭菌领域第一的市场地位。强生的其他职位包括McNeil Consumer Healthcare（Kenvue）、Centocor和瑞士Cilag Schaffhausen Operations（杨森制药）的财务管理职位。Scavilla先生在Globus医疗董事会任职，并且是提名和公司治理委员会的成员。他此前曾于2021年11月至2023年7月担任Impulse Dynamics的董事会成员，该公司是一家私营医疗技术公司，专注于心力衰竭患者的微创治疗方案。Scavilla先生在拉萨尔大学获得金融和组织行为学学士学位，在天普大学获得国际管理硕士学位。
- Daniel T. Scavilla,has served as a member of the Board and as a member of the Board's Audit and Finance Committee since February 2025. Mr. Scavilla served as President and Chief Executive Officer of Globus Medical, Inc. ("Globus Medical") from April 2022 through July 18, 2025, leading its acquisition of NuVasive, Inc. and overseeing the integration of the two organizations to create the second largest spine technology company in the world, a company with a market cap of approximately $8 billion. Prior to that, Mr. Scavilla was Executive Vice President, Chief Commercial Officer and President, Trauma, of Globus Medical where he scaled its manufacturing and distribution capabilities and launched its Orthopedics and Trauma business unit, and prior to that he was Chief Financial Officer of Globus Medical. Prior to joining Globus Medical, Mr. Scavilla spent 28 years in leadership roles across different businesses within Johnson & Johnson ("J&J"), including service as Chief Financial Officer, Worldwide Vice President Finance & Business Operations of J&J Vision Care, and as Chief Financial Officer, Worldwide Vice President Finance of Advanced Sterilization Products (J&J's infection prevention business within its MedTech business unit) helping to capture the number one market position in Sterilization. Additional roles at J&J included financial management positions at McNeil Consumer Healthcare (Kenvue), Centocor, and Cilag Schaffhausen Operations in Switzerland (Janssen Pharmaceutical). Mr. Scavilla serves on Globus Medical's Board of Directors and is a member of the Nominating and Corporate Governance Committee. He previously served on the board of directors of Impulse Dynamics, a privately held medical technology company focused on minimally invasive treatment options for heart failure patients, from November 2021 to July 2023. Mr. Scavilla received a B.S. in Finance and Organizational Behavior from LaSalle University and an M.B.A. in International Management from Temple University.
- Jonathan J. Mazelsky
-
Jonathan J. Mazelsky，自2019年10月起担任IDEXX Laboratories, Inc.的总裁兼首席执行官。在此之前，mazelsky先生于2019年6月至2019年10月担任IDEXX的临时总裁兼首席执行官，并于2012年8月至2019年6月担任执行副总裁，负责IDEXX北美Companion Animal Group 商业组织和创新组合的关键要素，包括IDEXX VetLab内部诊断、诊断成像、兽医软件和服务、快速检测和远程医疗业务线。加入IDEXX之前，他曾担任Philips Healthcare （Royal Philips Electronics（现命名为Royal Philips）的子公司）的计算机断层扫描、核医学和放射治疗规划高级副总裁兼总经理（从2010年到2012年）。在此之前，从2001年开始，他在Philips任职期间担任了一系列其他领导职务，并承担了越来越多的责任。加入Philips之前，他曾任职Agilent Technologies，从2000年到2002年担任执行主管，领导将Agilent的医疗保健集团整合到Philips。1997年至2000年，他还担任Agilent Technologies的医疗耗材业务部总经理。从1988年到1996年，他在Hewlett Packard担任财务、营销和商业规划方面的多个职位。他持有罗切斯特大学（University of Rochester）数学学士学位和芝加哥大学（University of Chicago）工商管理硕士学位。
Jonathan J. Mazelsky,has served as President and CEO of IDEXX since October 2019. Prior to that, Mr. Mazelsky served as Idexx Laboratories, Inc. Interim President and CEO from June 2019 to October 2019, and he was an Executive Vice President responsible for Idexx Laboratories, Inc. North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including Idexx Laboratories, Inc. IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business, from August 2012 to June 2019. Before joining IDEXX, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips). Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit at Agilent Technologies from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds an undergraduate degree in Mathematics from the University of Rochester and an MBA from the University of Chicago. - Jonathan J. Mazelsky，自2019年10月起担任IDEXX Laboratories, Inc.的总裁兼首席执行官。在此之前，mazelsky先生于2019年6月至2019年10月担任IDEXX的临时总裁兼首席执行官，并于2012年8月至2019年6月担任执行副总裁，负责IDEXX北美Companion Animal Group 商业组织和创新组合的关键要素，包括IDEXX VetLab内部诊断、诊断成像、兽医软件和服务、快速检测和远程医疗业务线。加入IDEXX之前，他曾担任Philips Healthcare （Royal Philips Electronics（现命名为Royal Philips）的子公司）的计算机断层扫描、核医学和放射治疗规划高级副总裁兼总经理（从2010年到2012年）。在此之前，从2001年开始，他在Philips任职期间担任了一系列其他领导职务，并承担了越来越多的责任。加入Philips之前，他曾任职Agilent Technologies，从2000年到2002年担任执行主管，领导将Agilent的医疗保健集团整合到Philips。1997年至2000年，他还担任Agilent Technologies的医疗耗材业务部总经理。从1988年到1996年，他在Hewlett Packard担任财务、营销和商业规划方面的多个职位。他持有罗切斯特大学（University of Rochester）数学学士学位和芝加哥大学（University of Chicago）工商管理硕士学位。
- Jonathan J. Mazelsky,has served as President and CEO of IDEXX since October 2019. Prior to that, Mr. Mazelsky served as Idexx Laboratories, Inc. Interim President and CEO from June 2019 to October 2019, and he was an Executive Vice President responsible for Idexx Laboratories, Inc. North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including Idexx Laboratories, Inc. IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business, from August 2012 to June 2019. Before joining IDEXX, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips). Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit at Agilent Technologies from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds an undergraduate degree in Mathematics from the University of Rochester and an MBA from the University of Chicago.
- Brian Gladden
-
Brian Gladden，现任Zelis Healthcare Inc（“Zelis”）的首席行政和首席财务官。在加入Zelis之前，他是Bain Capital北美私募股权团队的运营合伙人。加入Bain Capital之前，他曾担任上市公司Mondelēz International, Inc.和Dell, Inc.的首席财务官。他的职业生涯始于通用电气公司（General Electric Company），担任了近20年的各种高级财务和管理职位，包括GE Plastics的总裁兼首席执行官，以及塑料和医疗保健业务的部门首席财务官。他目前担任美国重症肌无力基金会主席，米勒斯维尔大学隆巴多商学院和德克萨斯大学奥斯汀分校麦库姆斯商学院咨询委员会成员。他拥有米勒斯维尔大学（Millersville University）工商管理和金融学士学位。
Brian Gladden,is currently the Chief Administrative and Chief Financial Officer of Zelis Healthcare Inc ("Zelis"). Before Zelis, Mr. Gladden was an Operating Partner with Bain Capital's North American Private Equity team. Prior to Bain Capital, Mr. Gladden was Chief Financial Officer at public companies Mondelēz International, Inc. and Dell, Inc. He began his career at General Electric Company, serving for nearly two decades in various senior finance and management positions, including as President and Chief Executive Officer of GE Plastics and divisional Chief Financial Officer roles in the Plastics and Healthcare businesses. Mr. Gladden currently serves as the Chair of the Myasthenia Gravis Foundation of America and as a member of the Advisory Councils for both the Lombardo College of Business at Millersville University and the McCombs School of Business at the University of Texas – Austin. He has a Bachelor of Science in Business Administration and Finance from Millersville University. - Brian Gladden，现任Zelis Healthcare Inc（“Zelis”）的首席行政和首席财务官。在加入Zelis之前，他是Bain Capital北美私募股权团队的运营合伙人。加入Bain Capital之前，他曾担任上市公司Mondelēz International, Inc.和Dell, Inc.的首席财务官。他的职业生涯始于通用电气公司（General Electric Company），担任了近20年的各种高级财务和管理职位，包括GE Plastics的总裁兼首席执行官，以及塑料和医疗保健业务的部门首席财务官。他目前担任美国重症肌无力基金会主席，米勒斯维尔大学隆巴多商学院和德克萨斯大学奥斯汀分校麦库姆斯商学院咨询委员会成员。他拥有米勒斯维尔大学（Millersville University）工商管理和金融学士学位。
- Brian Gladden,is currently the Chief Administrative and Chief Financial Officer of Zelis Healthcare Inc ("Zelis"). Before Zelis, Mr. Gladden was an Operating Partner with Bain Capital's North American Private Equity team. Prior to Bain Capital, Mr. Gladden was Chief Financial Officer at public companies Mondelēz International, Inc. and Dell, Inc. He began his career at General Electric Company, serving for nearly two decades in various senior finance and management positions, including as President and Chief Executive Officer of GE Plastics and divisional Chief Financial Officer roles in the Plastics and Healthcare businesses. Mr. Gladden currently serves as the Chair of the Myasthenia Gravis Foundation of America and as a member of the Advisory Councils for both the Lombardo College of Business at Millersville University and the McCombs School of Business at the University of Texas – Austin. He has a Bachelor of Science in Business Administration and Finance from Millersville University.
- Michael J. Barber
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Clyde R. Hosein
-
Clyde R. Hosein，2005年12月起，他是董事会成员；2013年8月起，他担任RingCentral（软件服务云为基础的商业通信解决方案供应商）行政副总裁兼首席财务官；2008年6月至2012年10月，他在Marvell Technology Group Ltd（高性能模拟，混合信号，数字信号处理和嵌入式微处理器集成电路的公开交易的半导体供应商）担任首席财务官；2008年10月至2010年3月，他还是Marvell Technology Group Ltd候补首席运营官兼秘书；2003年至2008年，他是Integrated Device Technology（重要混合信号半导体解决方案供应商）副总裁兼首席财务官；2001年至2003年，他是Advanced Interconnect Technologies（半导体封装和测试公司）财务部、行政部高级副总裁兼首席财务官。他还在Candescent Technologies（开发的平板显示技术开发商）担任过多个高级财务职位。在他的职业生涯早期，他在IBM Corporation的财务和工程方面工作14年。Hosein先生拥有纽约大学斯特恩商学院工商管理硕士学位和纽约理工大学工业工程学士学位。
Clyde R. Hosein has served as Chief Financial Officer of AliveCor Inc., a medical device and AI company producing ECG hardware and software for consumer mobile devices, since March 2021. Prior to AliveCor, Mr. Hosein served as Chief Financial Officer of Automation Anywhere, Inc., an enterprise software provider of robotic process automation, from December 2017 to March 2021. From August 2013 to May 2017 he served as Executive Vice President and Chief Financial Officer of RingCentral, Inc., a publicly traded provider of software-as-a-service cloud-based business communications solutions. Prior to this, Mr. Hosein served from June 2008 to October 2012 as Chief Financial Officer of Marvell Technology Group Ltd., a publicly traded semiconductor provider of high-performance analog, mixed-signal, digital signal processing and embedded microprocessor integrated circuits, and he also served as its Interim Chief Operating Officer and Secretary from October 2008 to March 2010. From 2003 to 2008 he served as Vice President and Chief Financial Officer of Integrated Device Technology, Inc., a provider of mixed-signal semiconductor solutions. From 2001 to 2003 he served as Senior Vice President, Finance and Administration and Chief Financial Officer of Advanced Interconnect Technologies, a semiconductor assembly and test company. He has also held other senior level financial positions, including the role of Chief Financial Officer at Candescent Technologies, a developer of flat panel display technology. Early in his career he spent 14 years in financial and engineering roles at IBM Corporation. Mr. Hosein has been a member of the Board of Directors of Wolfspeed, Inc. formerly Cree, Inc. since December 2005. - Clyde R. Hosein，2005年12月起，他是董事会成员；2013年8月起，他担任RingCentral（软件服务云为基础的商业通信解决方案供应商）行政副总裁兼首席财务官；2008年6月至2012年10月，他在Marvell Technology Group Ltd（高性能模拟，混合信号，数字信号处理和嵌入式微处理器集成电路的公开交易的半导体供应商）担任首席财务官；2008年10月至2010年3月，他还是Marvell Technology Group Ltd候补首席运营官兼秘书；2003年至2008年，他是Integrated Device Technology（重要混合信号半导体解决方案供应商）副总裁兼首席财务官；2001年至2003年，他是Advanced Interconnect Technologies（半导体封装和测试公司）财务部、行政部高级副总裁兼首席财务官。他还在Candescent Technologies（开发的平板显示技术开发商）担任过多个高级财务职位。在他的职业生涯早期，他在IBM Corporation的财务和工程方面工作14年。Hosein先生拥有纽约大学斯特恩商学院工商管理硕士学位和纽约理工大学工业工程学士学位。
- Clyde R. Hosein has served as Chief Financial Officer of AliveCor Inc., a medical device and AI company producing ECG hardware and software for consumer mobile devices, since March 2021. Prior to AliveCor, Mr. Hosein served as Chief Financial Officer of Automation Anywhere, Inc., an enterprise software provider of robotic process automation, from December 2017 to March 2021. From August 2013 to May 2017 he served as Executive Vice President and Chief Financial Officer of RingCentral, Inc., a publicly traded provider of software-as-a-service cloud-based business communications solutions. Prior to this, Mr. Hosein served from June 2008 to October 2012 as Chief Financial Officer of Marvell Technology Group Ltd., a publicly traded semiconductor provider of high-performance analog, mixed-signal, digital signal processing and embedded microprocessor integrated circuits, and he also served as its Interim Chief Operating Officer and Secretary from October 2008 to March 2010. From 2003 to 2008 he served as Vice President and Chief Financial Officer of Integrated Device Technology, Inc., a provider of mixed-signal semiconductor solutions. From 2001 to 2003 he served as Senior Vice President, Finance and Administration and Chief Financial Officer of Advanced Interconnect Technologies, a semiconductor assembly and test company. He has also held other senior level financial positions, including the role of Chief Financial Officer at Candescent Technologies, a developer of flat panel display technology. Early in his career he spent 14 years in financial and engineering roles at IBM Corporation. Mr. Hosein has been a member of the Board of Directors of Wolfspeed, Inc. formerly Cree, Inc. since December 2005.
- Leslie F. Varon
-
Leslie F. Varon，她是Xerox Corporation（文件解决方案公司）的前首席财务官（2015年11月至2016年12月）。从2017年1月到2017年3月，当她从公司退休时，她是当时新任施乐首席执行官的特别顾问。她在Xerox任职期间担任的领导职务包括：2015年3月至2015年10月担任投资者关系副总裁；从2006年7月到2015年2月，她担任财务副总裁兼公司财务总监，负责监督全球财务运营高管，并负责公司财务规划和分析、会计、内部审计、风险管理、全球房地产和全球共享服务中心；从2004年10月到2006年6月担任北美财务和运营支持副总裁；从1997年到2004年9月担任投资者关系副总裁和公司秘书；1993年至1997年担任公司审计总监。Varon自2018年1月起担任Dentsply Sirona， Inc.（牙科产品解决方案的制造商和分销商）的董事会成员，在那里她担任审计和财务委员会主席；自2017年5月起担任私人市场投资公司Hamilton Lane的审计委员会主席。2006年7月至2017年3月，她曾担任Xerox International Partners （Xerox和Fuji Xerox的合资企业）的董事会成员。Varon拥有Virginia Tech大学的工商管理硕士学位和Binghamton大学的心理学学士学位。
Leslie F. Varon,served as Chief Financial Officer of Xerox Corporation from November 2015 through December 2016 during which time she led the restructuring of the $18 billion business process services, printing equipment, software and solutions company, including the successful spin-off of its $7 billion services business. After that transaction, she became Special Advisor to the new Xerox Chief Executive Officer until March 2017 when she retired from the company. Prior to becoming Chief Financial Officer at Xerox, she was briefly Vice President of Investor Relations from March 2015 through October 2015. Before that, she served Xerox as Vice President of Finance & Corporate Controller from July 2006 to February 2015, where she oversaw global financial operating executives and had responsibility for corporate financial planning and analysis, accounting, internal audit, risk management, global real estate and worldwide shared services centers. Earlier in her career, Ms. Varon was Vice President Finance & Operations support for Xerox's North American business, Vice President Xerox Investor Relations and Corporate Secretary and Director of Corporate Audit. From 2006 to 2017, she served on the board of Xerox International Partners, a joint venture between Xerox Corporation and Fuji Xerox Corporation, representing Xerox Corporation's ownership stake. Ms. Varon serves on the board of Dentsply Sirona Inc. (Nasdaq: XRAY) and is Chair of its audit committee. She served on the board of Lam Research Corporation (Nasdaq: LRCX) until 2024.She received a B.A. from Binghamton University and an M.B.A. with concentrations in finance and marketing from Virginia Polytechnic Institute and State University. - Leslie F. Varon，她是Xerox Corporation（文件解决方案公司）的前首席财务官（2015年11月至2016年12月）。从2017年1月到2017年3月，当她从公司退休时，她是当时新任施乐首席执行官的特别顾问。她在Xerox任职期间担任的领导职务包括：2015年3月至2015年10月担任投资者关系副总裁；从2006年7月到2015年2月，她担任财务副总裁兼公司财务总监，负责监督全球财务运营高管，并负责公司财务规划和分析、会计、内部审计、风险管理、全球房地产和全球共享服务中心；从2004年10月到2006年6月担任北美财务和运营支持副总裁；从1997年到2004年9月担任投资者关系副总裁和公司秘书；1993年至1997年担任公司审计总监。Varon自2018年1月起担任Dentsply Sirona， Inc.（牙科产品解决方案的制造商和分销商）的董事会成员，在那里她担任审计和财务委员会主席；自2017年5月起担任私人市场投资公司Hamilton Lane的审计委员会主席。2006年7月至2017年3月，她曾担任Xerox International Partners （Xerox和Fuji Xerox的合资企业）的董事会成员。Varon拥有Virginia Tech大学的工商管理硕士学位和Binghamton大学的心理学学士学位。
- Leslie F. Varon,served as Chief Financial Officer of Xerox Corporation from November 2015 through December 2016 during which time she led the restructuring of the $18 billion business process services, printing equipment, software and solutions company, including the successful spin-off of its $7 billion services business. After that transaction, she became Special Advisor to the new Xerox Chief Executive Officer until March 2017 when she retired from the company. Prior to becoming Chief Financial Officer at Xerox, she was briefly Vice President of Investor Relations from March 2015 through October 2015. Before that, she served Xerox as Vice President of Finance & Corporate Controller from July 2006 to February 2015, where she oversaw global financial operating executives and had responsibility for corporate financial planning and analysis, accounting, internal audit, risk management, global real estate and worldwide shared services centers. Earlier in her career, Ms. Varon was Vice President Finance & Operations support for Xerox's North American business, Vice President Xerox Investor Relations and Corporate Secretary and Director of Corporate Audit. From 2006 to 2017, she served on the board of Xerox International Partners, a joint venture between Xerox Corporation and Fuji Xerox Corporation, representing Xerox Corporation's ownership stake. Ms. Varon serves on the board of Dentsply Sirona Inc. (Nasdaq: XRAY) and is Chair of its audit committee. She served on the board of Lam Research Corporation (Nasdaq: LRCX) until 2024.She received a B.A. from Binghamton University and an M.B.A. with concentrations in finance and marketing from Virginia Polytechnic Institute and State University.
- Willie A. Deese
-
Willie A. Deese， 自2008年起担任默克公司执行副总裁；自2005年起担任默克制造部总裁。2004年加入默克公司担任公司全球采购部高级副总裁；他曾担任葛兰素史克公司全球采购和物流高级副总裁以及永皇研究中心购买部副总裁。
Willie A. Deese,Director of PSE&G (wholly owned subsidiary of PSEG) since December 2023.EVP of Merck & Co. Inc., which develops, manufactures and distributes pharmaceuticals, from January 2008 until June 2016, President of Merck Manufacturing Division from 2005 until 2008, and SVP of Global Procurement at Merck from 2004 to 2005. Prior to that, SVP of Global Procurement and Logistics at GlaxoSmithKline, a pharmaceutical company. - Willie A. Deese， 自2008年起担任默克公司执行副总裁；自2005年起担任默克制造部总裁。2004年加入默克公司担任公司全球采购部高级副总裁；他曾担任葛兰素史克公司全球采购和物流高级副总裁以及永皇研究中心购买部副总裁。
- Willie A. Deese,Director of PSE&G (wholly owned subsidiary of PSEG) since December 2023.EVP of Merck & Co. Inc., which develops, manufactures and distributes pharmaceuticals, from January 2008 until June 2016, President of Merck Manufacturing Division from 2005 until 2008, and SVP of Global Procurement at Merck from 2004 to 2005. Prior to that, SVP of Global Procurement and Logistics at GlaxoSmithKline, a pharmaceutical company.
- Betsy D. Holden
-
Betsy D. Holden，2012年12月以来，她担任董事。2007年4月以来，她是McKinsey & Company（全球管理咨询公司）的高级顾问。从2004年1月到2005年5月，她担任Kraft Foods Inc.（ Altria Group, Inc.的食品单元）的全球营销和分类发展总裁。从2001年3月到2003年12月，她担任Kraft Foods Inc. 的首席执行官。从2000年5月到2003年12月，她担任Kraft Foods North America的总裁和首席执行官。1982年她的事业始于General Foods。她目前担任Western Union Company NYSE： WU和Diageo plc （NYSE： DEO）的董事。她在 Northwestern University's Kellogg School 的院长咨询委员会和Duke University's Trinity College的访客委员会任职。她获得Duke University的教育学士学位和Northwestern University的工商管理硕士学位。
Betsy D. Holden,held several leadership roles at Kraft Foods, including Co-Chief Executive Officer of Kraft Foods Inc., President, Global Marketing and Category Development of Kraft Foods Inc. and President and Chief Executive Officer of Kraft Foods North America. Ms. Holden has served on nine public boards over the last 20 years, including Diageo Plc (2009 to 2018) and Time, Inc. (2014 to 2018). She currently serves as a board member for Dentsply Sirona Inc., National Retail Properties, Inc., Western Union Company and several private portfolio companies of Paine Schwartz Partners, a private equity firm focused on sustainable agriculture and food products for which she sits on the Food Chain Advisory Board. She also serves on the Executive Committee of Duke University's Board of Trustees and the Global Advisory Board of Northwestern University's Kellogg School of Management. Ms. Holden holds a B.A. degree in Education from Duke University as well as an M.A. degree in Teaching and an MBA degree, each from Northwestern University. - Betsy D. Holden，2012年12月以来，她担任董事。2007年4月以来，她是McKinsey & Company（全球管理咨询公司）的高级顾问。从2004年1月到2005年5月，她担任Kraft Foods Inc.（ Altria Group, Inc.的食品单元）的全球营销和分类发展总裁。从2001年3月到2003年12月，她担任Kraft Foods Inc. 的首席执行官。从2000年5月到2003年12月，她担任Kraft Foods North America的总裁和首席执行官。1982年她的事业始于General Foods。她目前担任Western Union Company NYSE： WU和Diageo plc （NYSE： DEO）的董事。她在 Northwestern University's Kellogg School 的院长咨询委员会和Duke University's Trinity College的访客委员会任职。她获得Duke University的教育学士学位和Northwestern University的工商管理硕士学位。
- Betsy D. Holden,held several leadership roles at Kraft Foods, including Co-Chief Executive Officer of Kraft Foods Inc., President, Global Marketing and Category Development of Kraft Foods Inc. and President and Chief Executive Officer of Kraft Foods North America. Ms. Holden has served on nine public boards over the last 20 years, including Diageo Plc (2009 to 2018) and Time, Inc. (2014 to 2018). She currently serves as a board member for Dentsply Sirona Inc., National Retail Properties, Inc., Western Union Company and several private portfolio companies of Paine Schwartz Partners, a private equity firm focused on sustainable agriculture and food products for which she sits on the Food Chain Advisory Board. She also serves on the Executive Committee of Duke University's Board of Trustees and the Global Advisory Board of Northwestern University's Kellogg School of Management. Ms. Holden holds a B.A. degree in Education from Duke University as well as an M.A. degree in Teaching and an MBA degree, each from Northwestern University.
- Gregory T. Lucier
-
Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier is the chief executive officer of Corza Health, Inc. a company focused on acquiring healthcare companies and assets since April 2019. Prior to that, he served as Chairman and Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of Dentsply Sirona and a director at Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University. - Gregory T. Lucier，他一直担任董事会成员（2015年4月以来）。Lucier先生是Corza Health， Inc.（自2019年4月以来专注于收购医疗保健公司和资产的公司）的首席执行官。在此之前，他曾担任NuVasive， Inc.（医疗器械公司）的董事长兼首席执行官（2015年至2018年）。加入NuVasive之前，Lucier先生从2003年5月起担任Life Technologies Corporation（一家全球生物技术公司）的董事长兼首席执行官，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。在此之前，Lucier先生是通用电气公司的公司官员，在那里他担任各种领导职务。Lucier先生是Dentsply Sirona的董事长和Maravai LifeSciences的董事。此前，他曾担任Life Technologies Corporation（2003年5月至2014年2月）、Carefusion Corporation（2009年8月至2015年3月出售给Becton Dickinson）、Invuity, inc（2014年10月至2018年10月出售给Stryker）和Nuvasive（2013年12月至2021年5月）的董事。他持有Harvard Business School的工商管理硕士学位和Pennsylvania State大学的工业工程学士学位。
- Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier is the chief executive officer of Corza Health, Inc. a company focused on acquiring healthcare companies and assets since April 2019. Prior to that, he served as Chairman and Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of Dentsply Sirona and a director at Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Daniel T. Scavilla
Daniel T. Scavilla，自2025年2月起担任董事会成员以及董事会审计和财务委员会成员。Scavilla先生于2022年4月至2025年7月18日期间担任Globus Medical, Inc.（“Globus医疗”）的总裁兼首席执行官，领导其对NuVasive，Inc.的收购，并监督这两个组织的整合，以创建世界第二大脊柱技术公司，这家公司的市值约为80亿美元。在此之前，Scavilla先生是Globus医疗的执行副总裁、首席商务官兼Trauma总裁，在那里他扩展了制造和分销能力并推出了骨科和创伤业务部门，在此之前，他是Globus医疗的首席财务官。在加入Globus医疗之前，Scavilla先生在强生（“强生”）的不同业务中担任了28年的领导职务，包括担任J & J Vision Care全球财务与业务运营副总裁首席财务官，以及高级灭菌产品（强生医疗技术业务部门内的感染预防业务）全球财务副总裁首席财务官，帮助夺取灭菌领域第一的市场地位。强生的其他职位包括McNeil Consumer Healthcare（Kenvue）、Centocor和瑞士Cilag Schaffhausen Operations（杨森制药）的财务管理职位。Scavilla先生在Globus医疗董事会任职，并且是提名和公司治理委员会的成员。他此前曾于2021年11月至2023年7月担任Impulse Dynamics的董事会成员，该公司是一家私营医疗技术公司，专注于心力衰竭患者的微创治疗方案。Scavilla先生在拉萨尔大学获得金融和组织行为学学士学位，在天普大学获得国际管理硕士学位。
Daniel T. Scavilla,has served as a member of the Board and as a member of the Board's Audit and Finance Committee since February 2025. Mr. Scavilla served as President and Chief Executive Officer of Globus Medical, Inc. ("Globus Medical") from April 2022 through July 18, 2025, leading its acquisition of NuVasive, Inc. and overseeing the integration of the two organizations to create the second largest spine technology company in the world, a company with a market cap of approximately $8 billion. Prior to that, Mr. Scavilla was Executive Vice President, Chief Commercial Officer and President, Trauma, of Globus Medical where he scaled its manufacturing and distribution capabilities and launched its Orthopedics and Trauma business unit, and prior to that he was Chief Financial Officer of Globus Medical. Prior to joining Globus Medical, Mr. Scavilla spent 28 years in leadership roles across different businesses within Johnson & Johnson ("J&J"), including service as Chief Financial Officer, Worldwide Vice President Finance & Business Operations of J&J Vision Care, and as Chief Financial Officer, Worldwide Vice President Finance of Advanced Sterilization Products (J&J's infection prevention business within its MedTech business unit) helping to capture the number one market position in Sterilization. Additional roles at J&J included financial management positions at McNeil Consumer Healthcare (Kenvue), Centocor, and Cilag Schaffhausen Operations in Switzerland (Janssen Pharmaceutical). Mr. Scavilla serves on Globus Medical's Board of Directors and is a member of the Nominating and Corporate Governance Committee. He previously served on the board of directors of Impulse Dynamics, a privately held medical technology company focused on minimally invasive treatment options for heart failure patients, from November 2021 to July 2023. Mr. Scavilla received a B.S. in Finance and Organizational Behavior from LaSalle University and an M.B.A. in International Management from Temple University.- Daniel T. Scavilla，自2025年2月起担任董事会成员以及董事会审计和财务委员会成员。Scavilla先生于2022年4月至2025年7月18日期间担任Globus Medical, Inc.（“Globus医疗”）的总裁兼首席执行官，领导其对NuVasive，Inc.的收购，并监督这两个组织的整合，以创建世界第二大脊柱技术公司，这家公司的市值约为80亿美元。在此之前，Scavilla先生是Globus医疗的执行副总裁、首席商务官兼Trauma总裁，在那里他扩展了制造和分销能力并推出了骨科和创伤业务部门，在此之前，他是Globus医疗的首席财务官。在加入Globus医疗之前，Scavilla先生在强生（“强生”）的不同业务中担任了28年的领导职务，包括担任J & J Vision Care全球财务与业务运营副总裁首席财务官，以及高级灭菌产品（强生医疗技术业务部门内的感染预防业务）全球财务副总裁首席财务官，帮助夺取灭菌领域第一的市场地位。强生的其他职位包括McNeil Consumer Healthcare（Kenvue）、Centocor和瑞士Cilag Schaffhausen Operations（杨森制药）的财务管理职位。Scavilla先生在Globus医疗董事会任职，并且是提名和公司治理委员会的成员。他此前曾于2021年11月至2023年7月担任Impulse Dynamics的董事会成员，该公司是一家私营医疗技术公司，专注于心力衰竭患者的微创治疗方案。Scavilla先生在拉萨尔大学获得金融和组织行为学学士学位，在天普大学获得国际管理硕士学位。
- Daniel T. Scavilla,has served as a member of the Board and as a member of the Board's Audit and Finance Committee since February 2025. Mr. Scavilla served as President and Chief Executive Officer of Globus Medical, Inc. ("Globus Medical") from April 2022 through July 18, 2025, leading its acquisition of NuVasive, Inc. and overseeing the integration of the two organizations to create the second largest spine technology company in the world, a company with a market cap of approximately $8 billion. Prior to that, Mr. Scavilla was Executive Vice President, Chief Commercial Officer and President, Trauma, of Globus Medical where he scaled its manufacturing and distribution capabilities and launched its Orthopedics and Trauma business unit, and prior to that he was Chief Financial Officer of Globus Medical. Prior to joining Globus Medical, Mr. Scavilla spent 28 years in leadership roles across different businesses within Johnson & Johnson ("J&J"), including service as Chief Financial Officer, Worldwide Vice President Finance & Business Operations of J&J Vision Care, and as Chief Financial Officer, Worldwide Vice President Finance of Advanced Sterilization Products (J&J's infection prevention business within its MedTech business unit) helping to capture the number one market position in Sterilization. Additional roles at J&J included financial management positions at McNeil Consumer Healthcare (Kenvue), Centocor, and Cilag Schaffhausen Operations in Switzerland (Janssen Pharmaceutical). Mr. Scavilla serves on Globus Medical's Board of Directors and is a member of the Nominating and Corporate Governance Committee. He previously served on the board of directors of Impulse Dynamics, a privately held medical technology company focused on minimally invasive treatment options for heart failure patients, from November 2021 to July 2023. Mr. Scavilla received a B.S. in Finance and Organizational Behavior from LaSalle University and an M.B.A. in International Management from Temple University.
- Robert A. Johnson
Robert A. Johnson，于2022年11月加入Dentsply Sirona，目前担任首席供应链官。加入公司之前，Johnson先生是Cardinal Health的全球产品和供应链总裁。在此之前，他曾担任Becton Dickinson / CR Bard的高级副总裁，负责他们的介入部门，并在Baxter International工作了25年，在那里他在美国和国际上担任领导业务的职位。他在阿肯色大学（University of Arkansas）获得工业工程学士学位。
Robert A. Johnson,joined Dentsply Sirona in November 2022 and currently serves as Chief Supply Chain Officer. Prior to joining the Company, Mr. Johnson was President of Global Products and Supply Chain at Cardinal Health. Prior to that, he was Senior Vice President of Operations at Becton Dickinson / CR Bard where he was responsible for their Interventional Segment and spent 25 years with Baxter International where he held positions leading operations both in the United States and internationally. Mr. Johnson received his bachelor's degree in industrial engineering from the University of Arkansas.- Robert A. Johnson，于2022年11月加入Dentsply Sirona，目前担任首席供应链官。加入公司之前，Johnson先生是Cardinal Health的全球产品和供应链总裁。在此之前，他曾担任Becton Dickinson / CR Bard的高级副总裁，负责他们的介入部门，并在Baxter International工作了25年，在那里他在美国和国际上担任领导业务的职位。他在阿肯色大学（University of Arkansas）获得工业工程学士学位。
- Robert A. Johnson,joined Dentsply Sirona in November 2022 and currently serves as Chief Supply Chain Officer. Prior to joining the Company, Mr. Johnson was President of Global Products and Supply Chain at Cardinal Health. Prior to that, he was Senior Vice President of Operations at Becton Dickinson / CR Bard where he was responsible for their Interventional Segment and spent 25 years with Baxter International where he held positions leading operations both in the United States and internationally. Mr. Johnson received his bachelor's degree in industrial engineering from the University of Arkansas.
- Andrea L. Frohning
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Kevin J. Czerney
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介